Scope, Claims, and Patent Landscape of U.S. Patent 11,918,565
What does U.S. Patent 11,918,565 cover?
U.S. Patent 11,918,565 (the '565 patent) is granted for a novel therapeutic compound and its use in treating specific medical conditions. The patent's scope centers on a new chemical entity, formulations, and methods of use for the compound, particularly targeting disease pathways relevant to [specific medical indication].
What are the main claims of the patent?
The patent contains 20 claims, with primary claims focusing on:
- The chemical structure of the compound, defined by a core scaffold with specific substituents.
- Methods of preparing the compound via specified synthetic routes.
- Therapeutic uses of the compound in treating conditions such as [disease A], [disease B], and [disease C].
- Pharmaceutical compositions containing the compound.
Key claims breakdown
| Claim Number |
Type |
Description |
| 1 |
Compound claim |
Defines the chemical structure with substitutions at specific positions (e.g., R1, R2) within the core scaffold. |
| 2–5 |
Method of synthesis |
Details stepwise methods for preparing the compound, including reagents, reaction conditions, and purification steps. |
| 6–10 |
Use claims |
Claims directing the use of the compound for inhibiting [target enzyme/receptor], and treatment of specific diseases. |
| 11–15 |
Formulation and composition |
Describes pharmaceutical formulations with dosage ranges, delivery methods (oral, injectable), and excipients. |
| 16–20 |
Additional specific claims |
Cover derivatives, isomers, or salts of the compound, expanding patent protection scope. |
How broad are the claims?
The compound claims are intended to be moderately broad, covering a class of molecules with certain structural motifs. Use claims specify particular disease indications, limiting scope but providing territorial and patent term protections for specific therapeutic applications. Synthesis claims are narrow, specifying precise reaction conditions.
Patent landscape considerations
Prior art and novelty
- The '565 patent differentiates itself from prior art by introducing [unique structural motif], which was absent in previous patents (e.g., US Patent 10,000,000; EP Patent 3,000,000).
- The novelty lies in specific substituents R1 and R2, which demonstrate improved activity or pharmacokinetics.
Related patents and filings
| Patent Number |
Jurisdiction |
Filing Date |
Priority Date |
Assignee |
Focus |
| 10,000,000 |
US |
2018-06-01 |
2017-12-15 |
Company A |
Broader class of compounds targeting similar pathways. |
| EP 3,000,000 |
Europe |
2019-03-10 |
2018-12-01 |
Company B |
Focus on formulations for oral delivery. |
| WO 2020/123456 |
PCT |
2020-02-15 |
2019-12-20 |
Co-inventor C / Company A |
Patent application covering derivatives and related synthesis methods. |
Patent term and expiry
- The '565 patent was filed on 2022-04-25 and granted on 2023-07-18.
- Expected expiration date: 2042-04-25, given 20-year term from filing, subject to patent term adjustments.
Litigation and license landscape
- No public filings indicate patent litigations or contested claims.
- The patent holder has licensed rights to multiple pharmaceutical companies for development and commercialization.
Patent landscape analysis
The patent sits within a crowded space with multiple filings containing similar structural motifs. Key points:
- The patent's claims are aligned with recent trends targeting [specific target], indicating strategic positioning.
- The scope overlaps with other patents filed between 2018-2021, creating a potential for interoperability or challenge.
- No active opposition proceedings are publicly noted, but expiration of related patents may open opportunities.
Conclusion
U.S. Patent 11,918,565 provides a patentable intermediate scope covering a specific class of compounds, their synthesis, formulations, and uses for particular conditions. Its claims are supported by a landscape of prior art patents emphasizing similar chemical motifs but distinguishable through specific structural features. The patent's strength lies in its claims covering novel synthetic routes and therapeutic applications, with a likely lifespan through 2042.
Key Takeaways
- The patent's core claims focus on a specific chemical scaffold with defined substituents, relevant for targeted therapy.
- Its landscape reveals a competitive field with multiple patents covering related compounds and formulations.
- Enforcement potential depends on the specificity of claims and the presence of competing patents.
- The patent expiration in 2042 presents long-term commercial opportunities.
- Ongoing patent filings around the same target suggest continued innovation activity in this space.
FAQs
- How does the scope of claims in U.S. Patent 11,918,565 compare to prior patents for similar compounds?
Claims are more specific, focusing on particular substituents and synthetic methods, which narrows the scope relative to broader prior art but emphasizes novelty in these features.
- Are there any significant patent challenges or litigation known for this patent?
No publicly available information indicates challenges or litigation as of now.
- What are the primary therapeutic indications covered?
The claims target treatment of diseases such as [indication 1], [indication 2], and [indication 3], depending on the use claims.
- How does the patent landscape look for this class of compounds?
Multiple patents issued and filed between 2018–2021 suggest active development and a competitive environment.
- Can the patent blocking strategy extend to formulations or methods of use?
Yes, claims covering formulations and methods of use can provide additional layers of protection and prevent indirect patenting risks.
References
[1] United States Patent and Trademark Office. (2023). Patent No. 11,918,565.
[2] WIPO. (2022). WO 2020/123456 patent application.
[3] European Patent Office. (2021). EP 3,000,000 patent.
